Advertisement
Australia markets closed
  • ALL ORDS

    7,849.40
    +17.50 (+0.22%)
     
  • AUD/USD

    0.6528
    +0.0001 (+0.01%)
     
  • ASX 200

    7,587.00
    +17.10 (+0.23%)
     
  • OIL

    79.12
    +0.12 (+0.15%)
     
  • GOLD

    2,299.00
    -12.00 (-0.52%)
     
  • Bitcoin AUD

    89,607.71
    +1,820.06 (+2.07%)
     
  • CMC Crypto 200

    1,261.73
    -9.02 (-0.71%)
     

WELL Health Technologies' (TSE:WELL) investors will be pleased with their fantastic 719% return over the last five years

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held WELL Health Technologies Corp. (TSE:WELL) shares for the last five years, while they gained 719%. If that doesn't get you thinking about long term investing, we don't know what will. In the last week the share price is up 2.6%. We love happy stories like this one. The company should be really proud of that performance!

Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.

See our latest analysis for WELL Health Technologies

Because WELL Health Technologies made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

ADVERTISEMENT

For the last half decade, WELL Health Technologies can boast revenue growth at a rate of 60% per year. That's well above most pre-profit companies. Arguably, this is well and truly reflected in the strong share price gain of 52%(per year) over the same period. Despite the strong run, top performers like WELL Health Technologies have been known to go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
TSX:WELL Earnings and Revenue Growth December 27th 2023

WELL Health Technologies is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.

A Different Perspective

It's nice to see that WELL Health Technologies shareholders have received a total shareholder return of 46% over the last year. However, that falls short of the 52% TSR per annum it has made for shareholders, each year, over five years. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with WELL Health Technologies , and understanding them should be part of your investment process.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Canadian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.